Back

Significant reduction of Framingham risk score in hypogonadal men receiving long-term testosterone therapy: real-life evidence from a 10-year registry

28 August 2018 (10:05 - 10:55)
Organised by:
Congress Presentation Part of: Controversies in cardiovascular risk assessment and prevention Scores ESC Premium Access ESC Congress 2018

About the speaker

Photo
Professor Farid Saad

Bayer AG, Berlin (Germany)

6 More presentations in this session

Presentation thumbnail
Increased mortality despite successful multifactorial cardiovascular risk reduction in healthy men. 40-year follow-up of the Helsinki businessmen study intervention trial
Professor T. Strandberg (Helsinki, FI)
Abstract Slides
Presentation thumbnail
Assessing cardiovascular risk in people with atherosclerotic vascular disease on intensive statin therapy
Associate Professor B. Mihaylova (London, GB)
Abstract
Presentation thumbnail
Added predictive value of follow-up blood-pressure measurements after alteration of therapy on cardiovascular risk in patients with hypertension
Ms N. Jaspers (Utrecht, NL)
Abstract Slides
Presentation thumbnail
Optimizing outreach strategy to identify individuals at risk for diabetes and/or cardiovascular disease: a study of the Sodertalje municipality in Sweden
Doctor B. Shahim (Stockholm, SE)
Abstract Slides
Presentation thumbnail
Associations between very low concentrations of LDL-Cholesterol, hsCRP and health outcomes in the Reasons for Geographical and Racial Differences in Stroke (REGARDS) study
Professor M. Banach (Lodz, PL)
Abstract Slides

Access the full session

Session thumbnail
Controversies in cardiovascular risk assessment and prevention

The Event

Event poster

ESC Congress 2018

28 August 2018 10:05 CET
You may be interested in
thumbnail
Webinar
Risk assessment and lipid management in primary prevention
thumbnail
Webinar
Update on dyslipidaemia management: focus on risk estimation and lipoprotein(a)
thumbnail
ESC TV Today
Episode 26: Lp(a): the future starts now - Myocardial infarction in older age and frailty

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources